| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
REVIEW |
Centre for Reproductive Biology, Reproductive and Developmental Sciences, The University of Edinburgh, 51 Little France Crescent, Edinburgh EH16 4SU United Kingdom and 1 Centre for Cardiovascular Science, The University of Edinburgh, The Chancellors Building, 49 Little France Crescent, Edinburgh EH16 4SB United Kingdom
Correspondence should be addressed to F C Denison; Email: fiona.denison{at}ed.ac.uk
| Abstract |
|---|
|
|
|---|
| Introduction |
|---|
|
|
|---|
Normal human pregnancy involves adaptation of maternal vasculature to accommodate and sustain the developing foetus. Abnormal adaptation of the uterine vasculature is associated with deficient placentation and some diseases of pregnancy including pre-eclampsia and gestational diabetes are associated with systemic endothelial dysfunction (Brosens et al. 1972, McCarthy et al. 1993, Knock et al. 1997). We postulate that EPCs play an important role in development, regulation and maintenance of the vasculature during pregnancy. This review summarises our current understanding of the origin and function of EPCs, and highlights their potential role in angiogenesis and vascular repair in human pregnancy.
| Characterisation of circulating EPCs |
|---|
|
|
|---|
Co-expression of CD34 and KDR has been used in a number of experimental and clinical studies to identify circulating EPCs. No surface marker unique to endothelial progenitors has been identified and so it remains difficult to distinguish EPCs from mature endothelial cells that have been swept into the circulation or haematopoietic cells. CD133 is expressed by haematopoietic cells, but not by mature endothelial cells. Identification of CD133, KDR and CD34 co-expression may differentiate between circulating mature and progenitor endothelial cells (Peichev et al. 2000). The rarity of EPCs in peripheral blood (100200 cells/ml), has made their study difficult.
Alternative methods have been described for the characterisation and quantification of EPCs based on the culture of endothelial cells from circulating mononuclear cells. A number of functional assays have been reported, most involving the isolation of peripheral blood mononuclear cells by density centrifugation of blood and subsequent culture on fibronectin coated plates. After 57 days in culture, adherent colonies are seen, where spindle shaped cells emerge from a cluster of round cells (EPC colony forming units, EPC-CFUs). These adherent cells display a variety of endothelial-like properties including the uptake of acetylated low density lipoprotein (AcLDL) and staining with UEA-1 (Fig. 1
), a lectin of Ulex europaeus, specific for endothelial cells in a variety of tissues binding to the carbohydrate moiety
l-fucose (Stephenson et al. 1986).
|
Studies addressing the origin of EPCs have demonstrated that monocytes express endothelial lineage markers such as KDR and can differentiate into endothelial cells (Schmeisser et al. 2001). Rehman and colleagues found that the majority of EPC-CFUs expressed monocyte markers such as CD14, Mac-1, and CD11c, suggesting that peripheral blood EPCs are derived from monocyte-like cells (Rehman et al. 2003). The concept that functional endothelial cells may originate from a CD14+ progenitor is supported by reports that mature endothelial cells from human umbilical vein express CD14 (Jersmann et al. 2001) and that isolated CD14+ cells can improve neovascularisation after mouse hind limb ischaemia (Urbich et al. 2003). We present a diagram outlining two potential ways that endothelial cells might arise from haematopoietic stem cells via myeloid or endothelial progenitor subtypes (Fig. 2
).
|
|
| Mobilization and differentiation of EPCs |
|---|
|
|
|---|
The concept of a pool of endothelial progenitors in the bone-marrow, capable of moving to effect angiogenesis or vascular repair in response to ischaemia or vascular injury is supported by both in vitro and in vivo studies. In a mouse model, Asahara and colleagues demonstrated differentiation of donor bone marrow cells into endothelial cells and their subsequent incorporation into the vasculature during processes such as ovulation, wound healing, recovery from hind limb ischaemia and neoplasia (Asahara et al. 1999).
Reduced circulating EPC levels are observed when established cardiovascular risk factors are present suggesting a role for EPCs in the maintenance of endothelial function. Decreased numbers of EPCs have been demonstrated in cigarette smokers (Vasa et al. 2001) and in patients with diabetes mellitus (Tepper et al. 2002) or rheumatoid arthritis (Grisar et al. 2005). Hill et al.(2003) observed a strong correlation between the Framingham cardiovascular risk score (which uses cardiovascular risk factors to predict future risk of coronary artery disease (Wilson et al. 1987)) and circulating EPC numbers. EPC numbers predicted systemic endothelial function more accurately than the Framingham risk score (Hill et al. 2003). Furthermore, lower levels of EPCs are associated with adverse outcome in patients with coronary artery disease (Schmidt-Lucke et al. 2005, Werner et al. 2005) and impaired myocardial remodelling after infarction (Leone et al. 2005).
The postulated factors responsible for mobilization of EPCs from the bone marrow are the subject of an intense search. Such a factor might form a therapeutic strategy to enhance vascular repair. EPCs are released in the context of acute ischaemic injury, such as myocardial infarction (Leone et al. 2005, Massa et al. 2005) and following vascular injury as a consequence of coronary artery bypass grafting (Gill et al. 2001). Vascular endothelial growth factor (VEGF) and stromal cellderived factor-1 (SDF-1), both released from ischaemic tissue, are thought to be important factors in the mobilisation of EPCs. Other cytokines such as granulocyte-colony stimulating factor (G-CSF) and granulocyte-macrophage colony stimulating factor (GM-CSF) mobilise both haematological progenitors and EPCs. These have been used for many years to harvest progenitors for autologous bone marrow transplantation in the context of haematological malignancy. However, they also induce a pro-inflammatory state which may limit their therapeutic potential.
Mechanisms of EPC mobilisation in conditions other than ischaemia may be more relevant to understanding the role of EPCs in maternal circulation during pregnancy. The effect of oestrogens in maintaining endothelial function may be related to EPC mobilisation and enhanced vascular repair. In a rat-carotid injury model, exogenous oestradiol accelerates re-endothelialisation and attenuates medial thickening via mobilization and proliferation of bone marrow-derived EPCs. This response was absent in endothelial nitric oxide synthase (eNOS) knock out animals (Iwakura et al. 2003). Recent mouse studies with oestrogen receptor (ER)
and ß knockout animals demonstrate roles for both receptors
and ß in EPC-mediated neovascularisation in response to ischaemia. In addition, ER
messenger RNA expression was higher than ERß messenger RNA expression in EPCs. VEGF expression was significantly down-regulated on EPCs from ER
knockout mice compared with EPCs from wild type animals (Hamada et al. 2006).
| Vascular remodelling in pregnancy |
|---|
|
|
|---|
|
| Vascular and endothelial function in pregnancy |
|---|
|
|
|---|
Endothelial function is preserved in spite of the systemic inflammatory response associated with normal pregnancy. There is increased production of pro-inflammatory cytokines, including interleukin (IL)-6, IL-12, and tumour necrosis factor (TNF)-
with associated leucocytosis. The neutrophil count rises steadily throughout gestation, to peak at term (Austgulen et al. 1994, Rebelo et al. 1995, Melczer et al. 2003, Sacks et al. 2003). As well as being a pro-inflammatory state, normal pregnancy is associated with increased insulin resistance and hyperlipidaemia, controlled by hormonal changes. Pregnancy might be considered a stress test for the maternal vascular endothelium (Sattar & Greer 2002).
| Potential role of EPCs in normal pregnancy |
|---|
|
|
|---|
A second study by Gussin et al.(2002) supports this hypothesis. They cultured peripheral blood mononuclear cells from non-pregnant and pregnant women. Early outgrowth endothelial cells were formed from both groups. Late outgrowth cells, which have a higher proliferative potential, were only formed by the cells from pregnant women. The authors initially hypothesized that these cells were of fetal origin and their original intention was to optimise the culture of fetal cells. To identify fetal cells, they stained for X and Y chromosomes and discovered that none of the colonies contained fetal cells. They concluded that endothelial cells were of maternal origin and that pregnancy is associated with mobilization of EPCs into the circulation (Gussin et al. 2002).
In contrast, a study by Matsubara and colleagues of 36 healthy pregnant women observed decreasing numbers of circulating EPCs with increasing gestational age. They directly quantified EPCs by flow-cytometry, selecting for co-expression of CD34, CD133 and KDR. They also assessed EPC proliferation by counting cells that stained for both lectin Ulex europaeus and the uptake of acetylated-LDL after 7 days in culture. With increasing gestation, they found decreased numbers of these cells and decreased responses when stimulated by TNF-
and angiotensin II (Matsubara et al. 2006).
It is difficult to compare the results of these studies because different methods were used to count EPCs. It remains uncertain whether the cells measured by flow-cytometry are responsible for forming endothelial-like structures in cell culture. It is possible that the reduction in CD34+/CD133+/KDR+ cells is caused by dilution in expanding plasma volume. A limit of all three studies is the cross-sectional study design. Many factors affect circulating EPC numbers were not described for the study subjects. Prospective studies following women through gestation would provide more information about EPCs in pregnancy.
| Vascular dysfunction and EPCs in diseases of pregnancy |
|---|
|
|
|---|
Despite recent advances, the pathogenesis of pre-eclampsia remains unclear. Deficient placentation (decreased trophoblast invasion and subsequent spiral artery remodelling) is seen histologically in most women with pre-eclampsia (Brosens et al. 1972, Pijnenborg et al. 1991). Maternal endothelial dysfunction is a core feature of pre-eclampsia. Vascular cellular adhesion molecule-1 (VCAM), intercellular adhesion molecule-1 (ICAM), E-selectin, endothelin-1 and cellular fibronectin, all soluble markers of endothelial dysfunction are raised in the blood of women with pre-eclampsia. Some are evident before the clinical features of the disease (Taylor et al. 1991, Schiff et al. 1992, Kraayenbrink et al. 1993, Higgins et al. 1998, Bretelle et al. 2001). Other markers of endothelial dysfunction including asymmetric dimethylarginine (an endogenous inhibitor of nitric oxide synthesis) (Savvidou et al. 2003), plasminogen activator inhibitor type 1 (PAI-1) (Roes et al. 2002) and tissue plasminogen activator (t-PA) (Belo et al. 2002), also rise before clinical symptoms appear with t-PA correlating with the degree of proteinuria (Belo et al. 2002). Women with pre-eclampsia are more likely to have impaired uterine artery doppler waveforms (Campbell et al. 1983) and reduced flow-mediated dilation of the brachial artery at 2325 weeks gestation, suggesting that endothelial dysfunction precedes pre-eclampsia (Savvidou et al. 2003). Endothelial dysfunction, observed in pre-eclampsia, persists beyond pregnancy (Lampinen et al. 2006) and epidemiological data suggest an increased maternal risk of hypertension, coronary and cerebro-vascular disease (Wilson et al. 2003).
Pre-existing conditions associated with endothelial dysfunction, such as hypertension, renal disease, and diabetes, increase the risk of developing pre-eclampsia. Although there are extensive studies reporting decreased levels of EPCs or abnormal function of EPCs in men and non-pregnant women with these conditions, there are few available data about EPCs in pre-eclampsia. In addition, as with the studies in normal pregnancy, the published data are conflicting. Matsubara and colleagues reported no difference in the number of circulating EPCs measured by flow-cytometry in pre-eclamptic women although culture of mononuclear cells resulted in more endothelial-like cells. These cells had increased proliferative response following stimulation with TNF-
and angiotensin II compared with cells from women without pre-eclampsia (Matsubara et al. 2006). This increase may be a physiological response to ischaemia in the placenta and other organs, similar to that seen in myocardial infarction (Leone et al. 2005, Massa et al. 2005). In contrast, Sugawara et al. (2005b) demonstrated decreased numbers of EPC-CFUs and increased senescence of EPCs in patients with pre-eclampsia compared with gestationally matched controls (Sugawara et al. 2005b). These studies are not easily comparable because of the different methods used, and it is difficult to draw a conclusion from the discordant observations. It is likely that EPC function is more important than quantity, and ideally a subsequent study of EPCs in pre-eclampsia would assess number and function prospectively prior to the onset of disease.
| Postulated role of EPCs in pre-eclampsia |
|---|
|
|
|---|
|
| Future directions |
|---|
|
|
|---|
EPCs may also have a role in other pathologies of pregnancy such as gestational diabetes. Prospective longitudinal studies are required to assess EPC quantity and function during and after pregnancy. In addition, animal studies and in vitro models will provide us with a greater understanding of the role of EPCs in the maintenance of the endometrial vasculature and in placentation.
| Summary |
|---|
|
|
|---|
| Acknowledgements |
|---|
|
|
|---|
| Footnotes |
|---|
| References |
|---|
|
|
|---|
Anumba DO, Robson SC, Boys RJ & Ford GA 1999 Nitric oxide activity in the peripheral vasculature during normotensive and preeclamptic pregnancy. American Journal of Physiology 277 H848H854.
Asahara T, Masuda H, Takahashi T, Kalka C, Pastore C, Silver M, Kearne M, Magner M & Isner JM 1999 Bone marrow origin of EPCs responsible for postnatal vasculogenesis in physiological and pathological neovascularization. Circulation Research 85 221228.
Asahara T, Murohara T, Sullivan A, Silver M, van der Zee R, Witzenbichler B, Schatteman G & Isner JM 1997 Isolation of putative progenitor endothelial cells for angiogenesis. Science 275 964967.
Austgulen R, Lien E, Liabakk NB, Jacobsen G & Arntzen KJ 1994 Increased levels of cytokines and cytokine activity modifiers in normal pregnancy. European Journal of Obstetrics, Gynecology, and Reproductive Biology 57 149155.[CrossRef][ISI][Medline]
Belo L, Santos-Silva A, Rumley A, Lowe G, Pereira-Leite L, Quintanilha A & Rebelo I 2002 Elevated tissue plasminogen activator as a potential marker of endothelial dysfunction in pre-eclampsia: correlation with proteinuria. Bjog 109 12501255.[CrossRef][ISI][Medline]
Bretelle F, Sabatier F, Blann A, DErcole C, Boutiere B, Mutin M, Boubli L, Sampol J & Dignat-George F 2001 Maternal endothelial soluble cell adhesion molecules with isolated small for gestational age fetuses: comparison with pre-eclampsia. Bjog 108 12771282.[CrossRef][Medline]
Brosens I, Robertson WB & Dixon HG 1967 The physiological response of the vessels of the placental bed to normal pregnancy. Journal of Pathology and Bacteriology 93 569579.[CrossRef][ISI][Medline]
Brosens IA, Robertson WB & Dixon HG 1972 The role of the spiral arteries in the pathogenesis of preeclampsia. Obstetrics and Gynecology Annual 1 177191.[Medline]
Campbell S, Diaz-Recasens J, Griffin DR, Cohen-Overbeek TE, Pearce JM, Willson K & Teague MJ 1983 New doppler technique for assessing uteroplacental blood flow. Lancet 1 675677.[ISI][Medline]
Civin CI, Strauss LC, Brovall C, Fackler MJ, Schwartz JF & Shaper JH 1984 Antigenic analysis of hematopoiesis. III. A hematopoietic progenitor cell surface antigen defined by a monoclonal antibody raised against KG-1a cells. Journal of Immunology 133 157165.[Abstract]
Dorup I, Skajaa K & Sorensen KE 1999 Normal pregnancy is associated with enhanced endothelium-dependent flow-mediated vasodilation. American Journal of Physiology 276 H821H825.
Fina L, Molgaard HV, Robertson D, Bradley NJ, Monaghan P, Delia D, Sutherland DR, Baker MA & Greaves MF 1990 Expression of CD34 gene in vascular endothelial cells. Blood 75 24172426.
Gargett CE & Rogers PA 2001 Human endometrial angiogenesis. Reproduction 121 181186.[Abstract]
George J, Shmilovich H, Deutsch V, Miller H, Keren G & Roth A 2006 Comparative analysis of methods for assessment of circulating EPCs. Tissue Engineering 12 331335.[CrossRef][ISI][Medline]
Gill M, Dias S, Hattori K, Rivera ML, Hicklin D, Witte L, Girardi L, Yurt R, Himel H & Rafii S 2001 Vascular trauma induces rapid but transient mobilization of VEGFR2(+)AC133(+) endothelial precursor cells. Circulation Research 88 167174.
Ginsburg J & Duncan SL 1967 Peripheral blood flow in normal pregnancy. Cardiovascular Research 1 132137.[Medline]
Goodman RP, Killam AP, Brash AR & Branch RA 1982 Prostacyclin production during pregnancy: comparison of production during normal pregnancy and pregnancy complicated by hypertension. American Journal of Obstetrics and Gynecology 142 817822.[ISI][Medline]
Grisar J, Aletaha D, Steiner CW, Kapral T, Steiner S, Seidinger D, Weigel G, Schwarzinger I, Wolozcszuk W, Steiner G et al. 2005 Depletion of EPCs in the peripheral blood of patients with rheumatoid arthritis. Circulation 111 204211.
Gussin HA, Bischoff FZ, Hoffman R & Elias S 2002 Endothelial precursor cells in the peripheral blood of pregnant women. Journal for the Society for Gynecologic Investigation 9 357361.
Hamada H, Kim MK, Iwakura A, Ii M, Thorne T, Qin G, Asai J, Tsutsumi Y, Sekiguchi H, Silver M et al. 2006 Estrogen Receptors {alpha} and {beta} Mediate Contribution of Bone Marrow-Derived Endothelial Progenitor Cells to Functional Recovery After Myocardial Infarction. Circulation 114 22612270.
Higgins JR, Papayianni A, Brady HR, Darling MR & Walshe JJ 1998 Circulating vascular cell adhesion molecule-1 in pre-eclampsia, gestational hypertension, and normal pregnancy: evidence of selective dysregulation of vascular cell adhesion molecule-1 homeostasis in pre-eclampsia. American Journal of Obstetrics and Gynecology 179 464469.[CrossRef][ISI][Medline]
Hill JM, Zalos G, Halcox JP, Schenke WH, Waclawiw MA, Quyyumi AA & Finkel T 2003 Circulating EPCs, vascular function, and cardiovascular risk. New England Journal of Medicine 348 593600.
Imanishi T, Hano T & Nishio I 2005 Estrogen reduces endothelial progenitor cell senescence through augmentation of telomerase activity. Journal of Hypertension 23 16991706.[ISI][Medline]
Ingram DA, Caplice NM & Yoder MC 2005 Unresolved questions, changing definitions, and novel paradigms for defining EPCs. Blood 106 15251531.
Iwakura A, Luedemann C, Shastry S, Hanley A, Kearney M, Aikawa R, Isner JM, Asahara T & Losordo DW 2003 Estrogen-mediated, endothelial nitric oxide synthase-dependent mobilization of bone marrow-derived EPCs contributes to reendothelialization after arterial injury. Circulation 108 31153121.
Jersmann HP, Hii CS, Hodge GL & Ferrante A 2001 Synthesis and surface expression of CD14 by human endothelial cells. Infection and Immunity 69 479485.
Kalka C, Masuda H, Takahashi T, Gordon R, Tepper O, Gravereaux E, Pieczek A, Iwaguro H, Hayashi SI, Isner JM et al. 2000 Vascular endothelial growth factor(165) gene transfer augments circulating EPCs in human subjects. Circulation Research 86 11981202.
Karter Y, Aydin S, Curgunlu A, Uzun H, Erturk N, Vehid S, Kutlu A, Simsek G, Yucel R, Arat A et al. 2004 Endothelium and angiogenesis in white coat hypertension. Journal of Human Hypertension 18 809814.[CrossRef][ISI][Medline]
Knock GA, McCarthy AL, Lowy C & Poston L 1997 Association of gestational diabetes with abnormal maternal vascular endothelial function. British Journal of Obstetrics and Gynaecology 104 229234.[ISI][Medline]
Kraayenbrink AA, Dekker GA, van Kamp GJ & van Geijn HP 1993 Endothelial vasoactive mediators in preeclampsia. American Journal of Obstetrics and Gynecology 169 160165.[ISI][Medline]
Lampinen KH, Ronnback M, Kaaja RJ & Groop PH 2006 Impaired vascular dilatation in women with a history of pre-eclampsia. Journal of Hypertension 24 751756.[ISI][Medline]
Leone AM, Rutella S, Bonanno G, Abbate A, Rebuzzi AG, Giovannini S, Lombardi M, Galiuto L, Liuzzo G, Andreotti F et al. 2005 Mobilization of bone marrow-derived stem cells after myocardial infarction and left ventricular function. European Heart Journal 26 11961204.
Libby P 2002 Inflammation in atherosclerosis. Nature 420 868874.[CrossRef][Medline]
Massa M, Rosti V, Ferrario M, Campanelli R, Ramajoli I, Rosso R, De Ferrari GM, Ferlini M, Goffredo L, Bertoletti A et al. 2005 Increased circulating hematopoietic and EPCs in the early phase of acute myocardial infarction. Blood 105 199206.
Matsubara K, Abe E, Matsubara Y, Kameda K & Ito M 2006 Circulating EPCs during normal pregnancy and pre-eclampsia. American Journal of Reproductive Immunology 56 7985.[CrossRef]
Matthews W, Jordan CT, Gavin M, Jenkins NA, Copeland NG & Lemischka IR 1991 A receptor tyrosine kinase cDNA isolated from a population of enriched primitive hematopoietic cells and exhibiting close genetic linkage to c-kit. PNAS 88 90269030.
McCarthy AL, Woolfson RG, Raju SK & Poston L 1993 Abnormal endothelial cell function of resistance arteries from women with preeclampsia. American Journal of Obstetrics and Gynecology 168 13231330.[ISI][Medline]
Melczer Z, Banhidy F, Csomor S, Toth P, Kovacs M, Winkler G & Cseh K 2003 Influence of leptin and the TNF system on insulin resistance in pregnancy and their effect on anthropometric parameters of newborns. Acta Obstetricia et Gynecologica Scandinavica 82 432438.[CrossRef][ISI][Medline]
Mendelsohn ME & Karas RH 1999 The protective effects of estrogen on the cardiovascular system. New England Journal of Medicine 340 18011811.
Peichev M, Naiyer AJ, Pereira D, Zhu Z, Lane WJ, Williams M, Oz MC, Hicklin DJ, Witte L, Moore MA et al. 2000 Expression of VEGFR-2 and AC133 by circulating human CD34(+) cells identifies a population of functional endothelial precursors. Blood 95 952958.
Pijnenborg R, Anthony J, Davey DA, Rees A, Tiltman A, Vercruysse L & van Assche A 1991 A Placental bed spiral arteries in the hypertensive disorders of pregnancy. British Jounal of Obstetrics and Gynaecology 98 648655.
Pijnenborg R, Vercruysse L & Hanssens M 2006 The Uterine Spiral Arteries In Human Pregnancy: Facts and Controversies. Placenta 27 939958.[CrossRef][ISI][Medline]
Pirani BB, Campbell DM & MacGillivray I 1973 Plasma volume in normal first pregnancy. The Journal of Obstetrics and Gynaecology of the British Commonwealth 80 884887.[ISI][Medline]
Rebelo I, Carvalho-Guerra F, Pereira-Leite L & Quintanilha A 1995 Lactoferrin as a sensitive blood marker of neutrophil activation in normal pregnancies. European Journal of Obstetrics, Gynecology, and Reproductive Biology 62 189194.[CrossRef][ISI][Medline]
Rehman J, Li J, Orschell CM & March KL 2003 Peripheral blood EPCs are derived from monocyte/macrophages and secrete angiogenic growth factors. Circulation 107 11641169.
Reynolds LP & Redmer DA 2001 Angiogenesis in the placenta. Biology of Reproduction 64 10331040.
Roes EM, Sweep CG, Thomas CM, Zusterzeel PL, Geurts-Moespot A, Peters WH & Steegers EA 2002 Levels of plasminogen activators and their inhibitors in maternal and umbilical cord plasma in severe preeclampsia. American Journal of Obstetrics and Gynecology 187 10191025.[CrossRef][ISI][Medline]
Ross R 1999 Atherosclerosisan inflammatory disease. New England Journal of Medicine 340 115126.
Sacks GP, Redman CW & Sargent IL 2003 Monocytes are primed to produce the Th1 type cytokine IL-12 in normal human pregnancy: an intracellular flow cytometric analysis of peripheral blood mononuclear cells. Clinical and Experimental Immunology 131 490497.[CrossRef][ISI][Medline]
Sattar N & Greer IA 2002 Pregnancy complications and maternal cardiovascular risk: opportunities for intervention and screening?. BMJ 325 157160.
Savvidou MD, Hingorani AD, Tsikas D, Frolich JC, Vallance P & Nicolaides KH 2003 Endothelial dysfunction and raised plasma concentrations of asymmetric dimethylarginine in pregnant women who subsequently develop pre-eclampsia. Lancet 361 15111517.[CrossRef][ISI][Medline]
Schiff E, Ben-Baruch G, Peleg E, Rosenthal T, Alcalay M, Devir M & Mashiach S 1992 Immunoreactive circulating endothelin-1 in normal and hypertensive pregnancies. American Journal of Obstetrics and Gynecology 166 624628.[ISI][Medline]
Schmeisser A, Garlichs CD, Zhang H, Eskafi S, Graffy C, Ludwig J, Strasser RH & Daniel WG 2001 Monocytes coexpress endothelial and macrophagocytic lineage markers and form cord-like structures in Matrigel under angiogenic conditions. Cardiovascular Research 49 671680.
Schmidt-Lucke C, Rossig L, Fichtlscherer S, Vasa M, Britten M, Kamper U, Dimmeler S & Zeiher AM 2005 Reduced number of circulating EPCs predicts future cardiovascular events: proof of concept for the clinical importance of endogenous vascular repair. Circulation 111 29812987.
Shalaby F, Rossant J, Yamaguchi TP, Gertsenstein M, Wu XF, Breitman ML & Schuh AC 1995 Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice. Nature 376 6266.[CrossRef][Medline]
Shi Q, Rafii S, Wu MH, Wijelath ES, Yu C, Ishida A, Fujita Y, Kothari S, Mohle R, Sauvage LR et al. 1998 Evidence for circulating bone marrow-derived endothelial cells. Blood 92 362367.
Stephenson TJ, Griffiths DW & Mills PM 1986 Comparison of Ulex europaeus I lectin binding and factor VIII-related antigen as markers of vascular endothelium in follicular carcinoma of the thyroid. Histopathology 10 251260.[ISI][Medline]
Stone JL, Lockwood CJ, Berkowitz GS, Alvarez M, Lapinski R & Berkowitz RL 1994 Risk factors for severe preeclampsia. Obstetrics and Gynecology 83 357361.
Strehlow K, Werner N, Berweiler J, Link A, Dirnagl U, Priller J, Laufs K, Ghaeni L, Milosevic M, Bohm M et al. 2003 Estrogen increases bone marrow-derived endothelial progenitor cell production and diminishes neointima formation. Circulation 107 30593065.
Sugawara J, Mitsui-Saito M, Hoshiai T, Hayashi C, Kimura Y & Okamura K 2005a Circulating EPCs during human pregnancy. Journal of Clinical Endocrinology and Metabolism 90 18451848.
Sugawara J, Mitsui-Saito M, Hayashi C, Hoshiai T, Senoo M, Chisaka H, Yaegashi N & Okamura K 2005b Decrease and senescence of EPCs in patients with preeclampsia. Journal of Clinical Endocrinology and Metabolism 90 53295332.
Taylor RN, Crombleholme WR, Friedman SA, Jones LA, Casal DC & Roberts JM 1991 High plasma cellular fibronectin levels correlate with biochemical and clinical features of preeclampsia but cannot be attributed to hypertension alone. American Journal of Obstetrics and Gynecology 165 895901.[ISI][Medline]
Tepper OM, Galiano RD, Capla JM, Kalka C, Gagne PJ, Jacobowitz GR, Levine JP & Gurtner GC 2002 Human EPCs from type II diabetics exhibit impaired proliferation, adhesion, and incorporation into vascular structures. Circulation 106 27812786.
Ueland K, Novy MJ, Peterson EN & Metcalfe J 1969 Maternal cardiovascular dynamics. IV. The influence of gestational age on the maternal cardiovascular response to posture and exercise. American Journal of Obstetrics and Gynecology 104 856864.[ISI][Medline]
Urbich C, Aicher A, Heeschen C, Dernbach E, Hofmann WK, Zeiher AM & Dimmeler S 2005 Soluble factors released by EPCs promote migration of endothelial cells and cardiac resident progenitor cells. Journal of Molecular and Cellular Cardiology 39 733742.[CrossRef][ISI][Medline]
Urbich C, Heeschen C, Aicher A, Dernbach E, Zeiher AM & Dimmeler S 2003 Relevance of monocytic features for neovascularization capacity of circulating EPCs. Circulation 108 25112516.
Vasa M, Fichtlscherer S, Aicher A, Adler K, Urbich C, Martin H, Zeiher AM & Dimmeler S 2001 Number and migratory activity of circulating EPCs inversely correlate with risk factors for coronary artery disease. Circulation Research 89 E1E7.[ISI][Medline]
Wassmann S & Nickenig G 2003 Interrelationship of free oxygen radicals and endothelial dysfunctionmodulation by statins. Endothelium 10 2333.[CrossRef][ISI][Medline]
Weissberg PL & Bennett MR 1999 Atherosclerosisan inflammatory disease. New England Journal of Medicine 340 19281929.[CrossRef][ISI][Medline]
Werner N, Kosiol S, Schiegl T, Ahlers P, Walenta K, Link A, Bohm M & Nickenig G 2005 Circulating EPCs and cardiovascular outcomes. New England Journal of Medicine 353 9991007.
Williams DJ, Vallance PJ, Neild GH, Spencer JA & Imms FJ 1997 Nitric oxide-mediated vasodilation in human pregnancy. American Journal of Physiology 272 H748H752.
Wilson PW, Castelli WP & Kannel WB 1987 Coronary risk prediction in adults (the Framingham Heart Study). American Journal of Cardiology 59 91G94G.[CrossRef][Medline]
Wilson BJ, Watson MS, Prescott GJ, Sunderland S, Campbell DM, Hannaford P & Smith WC 2003 Hypertensive diseases of pregnancy and risk of hypertension and stroke in later life: results from cohort study. BMJ 326 845.
This article has been cited by other articles:
![]() |
C. K. Shapiro-Mendoza, K. M. Tomashek, M. Kotelchuck, W. Barfield, A. Nannini, J. Weiss, and E. Declercq Effect of Late-Preterm Birth and Maternal Medical Conditions on Newborn Morbidity Risk Pediatrics, February 1, 2008; 121(2): e223 - e232. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||